A survey by German analysts Roland Berger found that 65% of companies are facing a “strategic crisis”, with diversification the most common ploy to avert it.
The analysts’ Fight or Flight? study identifies three dimensions of diversification - innovate, integrate and de-risk, with the latter two proving most popular.
“Big pharmaceutical companies are at a turning point,” says Stephan Danner, partner and pharmaceutical expert at Roland Berger Strategy Consultants.
“With more than half of the industry's sales going off-patent within the next three years, 65% of the companies surveyed think the pharmaceutical industry is facing a strategic crisis.
via inpharm.com
No comments:
Post a Comment